These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 24090337)

  • 1. Prostate cancer screening for men aged 75 to 84 years in New South Wales.
    Carmichael LK; Goldsbury DE; O'Connell DL
    Aust N Z J Public Health; 2013 Oct; 37(5):492-4. PubMed ID: 24090337
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes?
    Carroll PR; Whitson JM; Cooperberg MR
    J Clin Oncol; 2011 Feb; 29(4):345-7. PubMed ID: 21189396
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostate cancer screening "reloaded".
    Gomella LG
    Can J Urol; 2010 Apr; 17(2):5057. PubMed ID: 20398441
    [No Abstract]   [Full Text] [Related]  

  • 4. In this issue: mini-theme on geriatric care and cancer screening.
    Bowman MA; Neale AV
    J Am Board Fam Med; 2009; 22(3):231-3. PubMed ID: 19429726
    [No Abstract]   [Full Text] [Related]  

  • 5. Summaries for patients. Screening smarter, not harder, for prostate cancer.
    Ann Intern Med; 2013 Feb; 158(3):I-30. PubMed ID: 23381056
    [No Abstract]   [Full Text] [Related]  

  • 6. Prostate-specific antigen, prostate cancer screening, and the pathologist: what should be our role?
    Jackson BR
    Arch Pathol Lab Med; 2013 Mar; 137(3):308-9. PubMed ID: 22799565
    [No Abstract]   [Full Text] [Related]  

  • 7. Prostate cancer: current evidence weighs against population screening.
    Boyle P; Brawley OW
    CA Cancer J Clin; 2009; 59(4):220-4. PubMed ID: 19564244
    [No Abstract]   [Full Text] [Related]  

  • 8. Early detection of prostate cancer. Role of prostate-specific antigen.
    Prabhakaran VM
    Can Fam Physician; 1996 Apr; 42():709-12. PubMed ID: 8653039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation.
    Catalona WJ; D'Amico AV; Fitzgibbons WF; Kosoko-Lasaki O; Leslie SW; Lynch HT; Moul JW; Rendell MS; Walsh PC
    Ann Intern Med; 2012 Jul; 157(2):137-8. PubMed ID: 22801676
    [No Abstract]   [Full Text] [Related]  

  • 10. How to use PSA to screen for prostate cancer.
    Little B; Young M
    Int J Clin Pract; 2003; 57(1):40-2. PubMed ID: 12587941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.
    Moyer VA;
    Ann Intern Med; 2012 Jul; 157(2):120-34. PubMed ID: 22801674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer screening: what we know, don't know, and believe.
    Brawley OW
    Ann Intern Med; 2012 Jul; 157(2):135-6. PubMed ID: 22801675
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
    Belpomme D; Irigaray P
    J Natl Cancer Inst; 2010 Apr; 102(7):506-7. PubMed ID: 20190186
    [No Abstract]   [Full Text] [Related]  

  • 14. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
    Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
    Barry MJ; Mulley AJ
    J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
    [No Abstract]   [Full Text] [Related]  

  • 16. Screening for prostate cancer: an updated review.
    Marta GN; Hanna SA; Fernandes da Silva JL; Carvalho Hde A
    Expert Rev Anticancer Ther; 2013 Jan; 13(1):101-8. PubMed ID: 23259431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Summaries for patients. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.
    Ann Intern Med; 2012 Jul; 157(2):I-44. PubMed ID: 22801691
    [No Abstract]   [Full Text] [Related]  

  • 18. Summaries for patients. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians.
    Ann Intern Med; 2013 May; 158(10):I-28. PubMed ID: 23567761
    [No Abstract]   [Full Text] [Related]  

  • 19. Prostate cancer screening.
    Catalona WJ
    BJU Int; 2004 Nov; 94(7):964-6. PubMed ID: 15541107
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.